Clinical trials in Caceres – page 2

151 clinical trials in Caceres, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Caceres at a glance

151

clinical trials

Paediatric trials0
Research sites1

Quick filters

151 trials in Caceres

Open in trial search

Acute myeloid leukaemia

Recruiting

A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

Registered drugNo placebo

A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cedazuridine
Sponsor:Fundacion PETHEMA

Contact Research Centre

Acute leukaemia

Recruiting

A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo

A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Sumitomo Pharma America Inc.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Syndax Pharmaceuticals Inc.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Quizartinib Dihydrochloride
Sponsor:Fundacion PETHEMA

Contact Research Centre

Acute myeloid leukaemia

Recruiting

A Study Comparing Two Treatment Schedules of Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Suitable for Intensive Treatment

Registered drugNo placebo

A Study Comparing Two Treatment Schedules of Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Suitable for Intensive Treatment

Registered drugNo placebo

Spain

Participants:65+ years
Substances:Azacitidine
Sponsor:Institut Gustave Roussy

Contact Research Centre

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:Relay Therapeutics Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

A Study of Metformin for Slowing Down Aging Effects in Patients with Chronic Obstructive Pulmonary Disease

Registered drug

A Study of Metformin for Slowing Down Aging Effects in Patients with Chronic Obstructive Pulmonary Disease

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Metformin Hydrochloride
Sponsor:Fundacion Instituto De Investigacion Sanitaria De Navarra

Contact Research Centre

Acute lymphocytic leukaemia+1

Recruiting

Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo

Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Ascentage Pharma Group Inc.

Contact Research Centre

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Janssen Cilag International

Contact Research Centre

Chronic myelomonocytic leukaemia+1

Recruiting

Study Comparing Oral Azacitidine and Cedazuridine with Subcutaneous Azacitidine for Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Registered drugNo placebo

Study Comparing Oral Azacitidine and Cedazuridine with Subcutaneous Azacitidine for Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Taiho Oncology Inc.

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

Study on Adding Darolutamide to First-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer Using a Drug Combination

Registered drugNo placebo

Study on Adding Darolutamide to First-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer Using a Drug Combination

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cabazitaxel
Sponsor:Swiss Group for Clinical Cancer Research

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Caceres

What the registry says about research in the country

01 Hematologic Malignancies

Clinical trials focusing on acute myeloid leukemia and related blood disorders, evaluating novel therapeutic combinations and treatment approaches.

Leukemia treatments
Drug combinations
Therapy resistance

Studies include investigations of eganelisib, RVU120, and other promising compounds for refractory conditions.

02 Cardiovascular Research

Innovative trials examining treatments for coronary artery disease and related cardiovascular conditions, including specialized therapies for arterial dissection.

Antiplatelet therapy
Stent technologies
Cardiovascular prevention

Research includes evaluation of novel medications and therapeutic approaches for various cardiac conditions.

03 Oncology Studies

Comprehensive research in breast cancer and melanoma, investigating targeted therapies and combination treatments for various cancer types.

Targeted therapies
Immunotherapy
Treatment resistance

Multiple trials exploring innovative treatment approaches for both early-stage and advanced cancers.

Back to Spain All countries